Health Care [ 7/12 ] | Biotechnology [ 32/75 ]
NASDAQ | Common Stock
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D.
It has strategic partnerships with Vertex Pharmaceuticals Incorporated.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 17, 26 | -1.37 Decreased by -211.36% | -1.17 Decreased by -17.09% |
| Nov 5, 25 | -1.17 Decreased by -15.84% | -1.31 Increased by +10.69% |
| Aug 4, 25 | -1.29 Increased by +13.42% | -1.40 Increased by +7.86% |
| May 6, 25 | -1.58 Decreased by -10.49% | -1.28 Decreased by -23.44% |
| Feb 11, 25 | -0.44 Decreased by -140.00% | -1.19 Increased by +62.89% |
| Nov 5, 24 | -1.01 Increased by +28.37% | -1.40 Increased by +27.86% |
| Aug 5, 24 | -1.49 Decreased by -52.04% | -1.52 Increased by +1.97% |
| May 8, 24 | -1.43 Decreased by -113.43% | -1.33 Decreased by -7.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 864.00 K Decreased by -97.53% | -130.61 M Decreased by -250.07% | Decreased by -15.12 K% Decreased by -14.08 K% |
| Sep 30, 25 | 889.00 K Increased by +47.67% | -106.44 M Decreased by -23.85% | Decreased by -11.97 K% Increased by +16.13% |
| Jun 30, 25 | 892.00 K Increased by +72.53% | -208.55 M Decreased by -64.98% | Decreased by -23.38 K% Increased by +4.38% |
| Mar 31, 25 | 865.00 K Increased by +71.63% | -136.00 M Decreased by -16.64% | Decreased by -15.72 K% Increased by +32.04% |
| Dec 31, 24 | 35.00 M Decreased by -82.50% | -37.31 M Decreased by -141.76% | Decreased by -106.60% Decreased by -338.63% |
| Sep 30, 24 | 602.00 K Increased by +N/A% | -85.94 M Increased by +23.37% | Decreased by -14.28 K% Decreased by N/A% |
| Jun 30, 24 | 517.00 K Decreased by -99.26% | -126.41 M Decreased by -62.60% | Decreased by -24.45 K% Decreased by -21.92 K% |
| Mar 31, 24 | 504.00 K Decreased by -99.50% | -116.59 M Decreased by -119.71% | Decreased by -23.13 K% Decreased by -43.49 K% |